• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

先天免疫系统白细胞的调节作为预防 1 型糖尿病发生和进展的一种潜在方法。

Modulation of Leukocytes of the Innate Arm of the Immune System as a Potential Approach to Prevent the Onset and Progression of Type 1 Diabetes.

机构信息

San Raffaele Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.

Department of Pathology, Immunology and Laboratory Medicine, Diabetes Institute, College of Medicine, University of Florida, Gainesville, FL.

出版信息

Diabetes. 2021 Feb;70(2):313-322. doi: 10.2337/dbi20-0026.

DOI:10.2337/dbi20-0026
PMID:33472941
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7881863/
Abstract

Type 1 diabetes (T1D) is characterized by insulin deficiency resulting from the selective destruction of pancreatic β-cells by self-reactive T cells. Recent evidence demonstrates that innate immune responses substantially contribute to the pathogenesis of T1D, as they represent a first line of response to danger/damage signals. Here we discuss evidence on how, in a relapsing-remitting pattern, pancreas remodeling, diet, microbiota, gut permeability, and viral/bacterial infections induce the accumulation of leukocytes of the innate arm of the immune system throughout the pancreas. The subsequent acquisition and presentation of endocrine and exocrine antigens to the adaptive arm of the immune system results in a chronic progression of pancreatic damage. This process provides for the generation of self-reactive T-cell responses; however, the relative weight that genetic and environmental factors have on the etiopathogenesis of T1D is endotype imprinted and patient specific. With this Perspectives in Diabetes, our goal is to encourage the scientific community to rethink mechanisms underlying T1D pathogenesis and to consider therapeutic approaches that focus on these processes in intervention trials within new-onset disease as well as in efforts seeking the disorder's prevention in individuals at high risk.

摘要

1 型糖尿病(T1D)的特征是由于自身反应性 T 细胞对胰腺β细胞的选择性破坏导致胰岛素缺乏。最近的证据表明,固有免疫反应在 T1D 的发病机制中起重要作用,因为它们是对危险/损伤信号的第一道反应。在这里,我们讨论了在复发缓解模式下,胰腺重塑、饮食、微生物群、肠道通透性和病毒/细菌感染如何导致固有免疫系统的白细胞在整个胰腺中积累的证据。随后,内分泌和外分泌抗原被适应性免疫系统获取和呈递,导致胰腺损伤的慢性进展。这一过程为自身反应性 T 细胞反应的产生提供了条件;然而,遗传和环境因素对 T1D 发病机制的相对权重是受表型印记和患者特异性影响的。通过这篇糖尿病视角文章,我们的目标是鼓励科学界重新思考 T1D 发病机制背后的机制,并考虑在新发病例中以及在高危人群中预防该疾病的努力中,针对这些过程的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/291f/7881863/ebe4804238f3/dbi200026f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/291f/7881863/ebe4804238f3/dbi200026f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/291f/7881863/ebe4804238f3/dbi200026f1.jpg

相似文献

1
Modulation of Leukocytes of the Innate Arm of the Immune System as a Potential Approach to Prevent the Onset and Progression of Type 1 Diabetes.先天免疫系统白细胞的调节作为预防 1 型糖尿病发生和进展的一种潜在方法。
Diabetes. 2021 Feb;70(2):313-322. doi: 10.2337/dbi20-0026.
2
From immunohistological to anatomical alterations of human pancreas in type 1 diabetes: New concepts on the stage.从 1 型糖尿病患者胰腺的免疫组织化学改变到解剖学改变:分期的新概念。
Diabetes Metab Res Rev. 2020 May;36(4):e3264. doi: 10.1002/dmrr.3264. Epub 2019 Dec 30.
3
Innate Immunity Mediated Inflammation and Beta Cell Function: Neighbors or Enemies?先天免疫介导的炎症与β细胞功能:是敌是友?
Front Endocrinol (Lausanne). 2021 Feb 8;11:606332. doi: 10.3389/fendo.2020.606332. eCollection 2020.
4
The role of the innate immune system in destruction of pancreatic beta cells in NOD mice and humans with type I diabetes.天然免疫系统在NOD小鼠和I型糖尿病患者胰腺β细胞破坏中的作用。
J Autoimmun. 2016 Jul;71:26-34. doi: 10.1016/j.jaut.2016.03.006. Epub 2016 Mar 24.
5
Immunopathology of the human pancreas in type-I diabetes.I 型糖尿病患者胰腺的免疫病理学。
Semin Immunopathol. 2011 Jan;33(1):9-21. doi: 10.1007/s00281-010-0205-0. Epub 2010 Apr 28.
6
Increased Hormone-Negative Endocrine Cells in the Pancreas in Type 1 Diabetes.1型糖尿病患者胰腺中激素阴性内分泌细胞增多。
J Clin Endocrinol Metab. 2016 Sep;101(9):3487-96. doi: 10.1210/jc.2016-1350. Epub 2016 Jun 14.
7
Neoepitopes in Type 1 Diabetes: Etiological Insights, Biomarkers and Therapeutic Targets.1 型糖尿病中的新抗原:病因学见解、生物标志物和治疗靶点。
Front Immunol. 2021 Apr 19;12:667989. doi: 10.3389/fimmu.2021.667989. eCollection 2021.
8
The pathogenic "symphony" in type 1 diabetes: A disorder of the immune system, β cells, and exocrine pancreas.1 型糖尿病中的致病“交响乐”:免疫系统、β 细胞和外分泌胰腺的紊乱。
Cell Metab. 2023 Sep 5;35(9):1500-1518. doi: 10.1016/j.cmet.2023.06.018. Epub 2023 Jul 20.
9
New Evidence of Exocrine Pancreatopathy in Pre-symptomatic and Symptomatic Type 1 Diabetes.新证据表明 1 型糖尿病在症状前和症状期存在外分泌胰腺病变。
Curr Diab Rep. 2019 Aug 31;19(10):92. doi: 10.1007/s11892-019-1223-5.
10
Organ donor specimens: What can they tell us about type 1 diabetes?器官捐献者标本:它们能告诉我们关于1型糖尿病的哪些信息?
Pediatr Diabetes. 2015 Aug;16(5):320-30. doi: 10.1111/pedi.12286. Epub 2015 May 22.

引用本文的文献

1
Dysregulation and therapeutic prospects of regulatory T cells in type 1 diabetes.1型糖尿病中调节性T细胞的失调与治疗前景
Acta Diabetol. 2025 Mar 21. doi: 10.1007/s00592-025-02478-3.
2
CD56 Expression in Spleen Tissue Pathology and Its Implications in the Development of Type 1 Diabetes: Insights from Diabetic Rat Models.CD56在脾脏组织病理学中的表达及其在1型糖尿病发病中的意义:来自糖尿病大鼠模型的见解
Med Arch. 2024;78(4):274-278. doi: 10.5455/medarh.2024.78.274-278.
3
Nanoparticle-neutrophils interactions for autoimmune regulation.

本文引用的文献

1
A patent review of myeloperoxidase inhibitors for treating chronic inflammatory syndromes (focus on cardiovascular diseases, 2013-2019).一篇关于髓过氧化物酶抑制剂治疗慢性炎症综合征的专利回顾(重点关注心血管疾病,2013-2019 年)。
Expert Opin Ther Pat. 2020 Aug;30(8):595-608. doi: 10.1080/13543776.2020.1780210. Epub 2020 Jun 18.
2
Large-scale electron microscopy database for human type 1 diabetes.人类 1 型糖尿病的大规模电子显微镜数据库。
Nat Commun. 2020 May 18;11(1):2475. doi: 10.1038/s41467-020-16287-5.
3
Decreased pancreatic acinar cell number in type 1 diabetes.
纳米颗粒-中性粒细胞相互作用的自身免疫调控。
Adv Drug Deliv Rev. 2024 Jun;209:115316. doi: 10.1016/j.addr.2024.115316. Epub 2024 Apr 23.
4
Gut microbiome and metabolic activity in type 1 diabetes: An analysis based on the presence of GADA.1 型糖尿病患者的肠道微生物组和代谢活性:基于 GADA 存在的分析。
Front Endocrinol (Lausanne). 2022 Sep 30;13:938358. doi: 10.3389/fendo.2022.938358. eCollection 2022.
5
The Contribution of Neutrophils and NETs to the Development of Type 1 Diabetes.中性粒细胞和 NETs 对 1 型糖尿病发展的贡献。
Front Immunol. 2022 Jul 6;13:930553. doi: 10.3389/fimmu.2022.930553. eCollection 2022.
6
Circulating platelet-neutrophil aggregates characterize the development of type 1 diabetes in humans and NOD mice.循环血小板-中性粒细胞聚集体可作为人类和 NOD 小鼠 1 型糖尿病发展的特征。
JCI Insight. 2022 Jan 25;7(2):e153993. doi: 10.1172/jci.insight.153993.
7
Emerging Roles of Myeloid-Derived Suppressor Cells in Diabetes.髓源性抑制细胞在糖尿病中的新作用
Front Pharmacol. 2021 Dec 16;12:798320. doi: 10.3389/fphar.2021.798320. eCollection 2021.
8
Type I IFN-Driven Immune Cell Dysregulation in Rat Autoimmune Diabetes.I 型干扰素驱动的大鼠自身免疫性糖尿病免疫细胞失调。
Immunohorizons. 2021 Oct 26;5(10):855-869. doi: 10.4049/immunohorizons.2100088.
9
Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential.二甲双胍降低 COVID-19 严重程度和死亡率:分子机制和治疗潜力。
Biomed Pharmacother. 2021 Dec;144:112230. doi: 10.1016/j.biopha.2021.112230. Epub 2021 Oct 6.
1 型糖尿病患者胰腺腺泡细胞数量减少。
Diabetologia. 2020 Jul;63(7):1418-1423. doi: 10.1007/s00125-020-05155-y. Epub 2020 May 9.
4
Neutrophil Extracellular Traps (NETs) Take the Central Stage in Driving Autoimmune Responses.中性粒细胞胞外诱捕网(NETs)在驱动自身免疫反应中占据中心舞台。
Cells. 2020 Apr 8;9(4):915. doi: 10.3390/cells9040915.
5
Single-cell RNA sequencing of murine islets shows high cellular complexity at all stages of autoimmune diabetes.单细胞 RNA 测序显示,在自身免疫性糖尿病的所有阶段,胰岛具有高度的细胞复杂性。
J Exp Med. 2020 Jun 1;217(6). doi: 10.1084/jem.20192362.
6
The Association of Autoimmune Diseases with Type 1 Diabetes Mellitus in Children Depends Also by the Length of Partial Clinical Remission Phase (Honeymoon).儿童自身免疫性疾病与1型糖尿病的关联也取决于部分临床缓解期(蜜月期)的时长。
Int J Endocrinol. 2020 Jan 4;2020:2630827. doi: 10.1155/2020/2630827. eCollection 2020.
7
High residual C-peptide likely contributes to glycemic control in type 1 diabetes.高残余 C 肽可能有助于 1 型糖尿病的血糖控制。
J Clin Invest. 2020 Apr 1;130(4):1850-1862. doi: 10.1172/JCI134057.
8
Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.引入表型概念以应对 1 型糖尿病疾病异质性的挑战。
Diabetes Care. 2020 Jan;43(1):5-12. doi: 10.2337/dc19-0880. Epub 2019 Nov 21.
9
Pharmacological Inhibitors of the NLRP3 Inflammasome.NLRP3 炎性小体的药理学抑制剂。
Front Immunol. 2019 Oct 25;10:2538. doi: 10.3389/fimmu.2019.02538. eCollection 2019.
10
OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis.OLT1177(达帕努司他),一种选择性 NLRP3 炎性体抑制剂,可改善实验性自身免疫性脑脊髓炎发病机制。
Front Immunol. 2019 Nov 1;10:2578. doi: 10.3389/fimmu.2019.02578. eCollection 2019.